Regeneron Pharmaceuticals, Inc. (REGN) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Tarrytown, NY, アメリカ. 現CEOは Leonard S. Schleifer.
REGN を有する IPO日 1991-04-02, 15,158 名の正社員, に上場 NASDAQ Global Select, 時価総額 $78.5B.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines for serious diseases. The company's marketed portfolio includes EYLEA for retinal diseases, Dupixent for atopic dermatitis and asthma, Libtayo for cutaneous squamous cell carcinoma, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and several other specialized therapies for infectious, rare, and cancerous conditions. Regeneron maintains extensive collaboration agreements with leading pharmaceutical and biotechnology companies including Sanofi, Bayer, Roche, and AstraZeneca, as well as strategic partnerships with research institutions and government health agencies. Founded in 1988 and headquartered in Tarrytown, New York, the company focuses on high-value therapeutic areas including ophthalmology, immunology, cardiovascular disease, and oncology.
